Franklin Resources Inc. Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Franklin Resources Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 35.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 180,471 shares of the medical equipment provider's stock after selling 97,824 shares during the quarter. Franklin Resources Inc. owned about 0.08% of Hologic worth $13,010,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HOLX. HighTower Advisors LLC increased its position in shares of Hologic by 9.8% during the third quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider's stock valued at $1,832,000 after acquiring an additional 2,012 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after purchasing an additional 800 shares during the last quarter. Quantinno Capital Management LP raised its position in Hologic by 10.9% in the third quarter. Quantinno Capital Management LP now owns 41,424 shares of the medical equipment provider's stock valued at $3,374,000 after purchasing an additional 4,063 shares during the period. Stifel Financial Corp raised its position in Hologic by 115.8% in the third quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider's stock valued at $1,658,000 after purchasing an additional 10,924 shares during the period. Finally, Insigneo Advisory Services LLC acquired a new position in Hologic during the third quarter worth $457,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Evercore ISI cut their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Raymond James reissued an "outperform" rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Stock Up 1.2 %

NASDAQ HOLX traded up $0.69 during trading on Friday, reaching $57.85. 4,235,273 shares of the company's stock were exchanged, compared to its average volume of 1,909,933. The company has a 50 day moving average price of $62.47 and a two-hundred day moving average price of $71.55. The stock has a market cap of $12.98 billion, a P/E ratio of 18.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 1 year low of $56.27 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.